Literature DB >> 14552515

Post-infectious acute cerebellar ataxia in children.

Moshe Nussinovitch1, Dario Prais, Benjamin Volovitz, Rivka Shapiro, Jacob Amir.   

Abstract

Acute cerebellar ataxia is a relatively common neurologic disorder among children. Our aim was to characterize the clinical picture, etiology, and prognosis of acute cerebellar ataxia. The medical records of all children with a diagnosis of acute cerebellar ataxia hospitalized in our center and Hasharon Medical Center from 1990 to 2001 were reviewed. The diagnosis of acute cerebellar ataxia was based on the following criteria: acute onset of ataxia with or without nystagmus; absence of known genetic predisposing factors, such as familial degenerative disorders; and absence of drug intoxication, bacterial meningitis, and metabolic disorders. Thirty-nine children were identified; 54% were male; mean age at presentation was 4.8 +/- 3.8 years. All patients were observed for at least 1 year. A prodromal febrile illness was noted in 74.4%: varicella, 31%; mumps, 20%; nonspecific viral infection, 15.4%; mycoplasma, 5%; Epstein Barr virus, 3%. Latency from the prodromal illness to the onset of ataxia was 8.8 +/- 7.4 days. The most common associated neurologic findings were nystagmus and dysmetria. Full gait recovery took less than 2 weeks on average, and the longest duration of neurologic signs was 24 days (mumps-related). Acute cerebellar ataxia in childhood is a self-limited disease. The recovery was faster than that reported in previous publications and was complete in all children without any neurologic sequelae. Imaging studies are needed only in atypical presentation or if there is no spontaneous improvement after 1 to 2 weeks.

Entities:  

Mesh:

Year:  2003        PMID: 14552515     DOI: 10.1177/000992280304200702

Source DB:  PubMed          Journal:  Clin Pediatr (Phila)        ISSN: 0009-9228            Impact factor:   1.168


  9 in total

Review 1.  Acquired ataxias: the clinical spectrum, diagnosis and management.

Authors:  Wolfgang Nachbauer; Andreas Eigentler; Sylvia Boesch
Journal:  J Neurol       Date:  2015-03-26       Impact factor: 4.849

2.  Anti-dipeptidyl-peptidase-like protein 6 encephalitis with pure cerebellar ataxia: a case report.

Authors:  Jing Lin; Min Zhu; Xiaocheng Mao; Zeqing Jin; Meihong Zhou; Daojun Hong
Journal:  BMC Neurol       Date:  2022-07-01       Impact factor: 2.903

Review 3.  Molecular biology, pathogenesis and pathology of mumps virus.

Authors:  Steven Rubin; Michael Eckhaus; Linda J Rennick; Connor G G Bamford; W Paul Duprex
Journal:  J Pathol       Date:  2015-01       Impact factor: 7.996

4.  Intravenous immunoglobulins in an adult case of post-EBV cerebellitis.

Authors:  Eleonora D'Ambrosio; Farnaz Khalighinejad; Carolina Ionete
Journal:  BMJ Case Rep       Date:  2020-02-18

Review 5.  Cerebellar Degeneration in Epilepsy: A Systematic Review.

Authors:  Manar Ibdali; Marios Hadjivassiliou; Richard A Grünewald; Priya D Shanmugarajah
Journal:  Int J Environ Res Public Health       Date:  2021-01-08       Impact factor: 3.390

Review 6.  Personalization of medical treatments in oncology: time for rethinking the disease concept to improve individual outcomes.

Authors:  Mariano Bizzarri; Valeria Fedeli; Noemi Monti; Alessandra Cucina; Maroua Jalouli; Saleh H Alwasel; Abdel Halim Harrath
Journal:  EPMA J       Date:  2021-10-07       Impact factor: 6.543

7.  Post-dengue parkinsonism.

Authors:  Shahrul Azmin; Ramesh Sahathevan; Zainudin Suehazlyn; Zhe Kang Law; Remli Rabani; Wan Yahya Nafisah; Hui Jan Tan; Mohamed Ibrahim Norlinah
Journal:  BMC Infect Dis       Date:  2013-04-18       Impact factor: 3.090

8.  Acute cerebellitis following SARS-CoV-2 infection: A case report and review of the literature.

Authors:  Maria Camila Moreno-Escobar; Parissa Feizi; Sanjiti Podury; Medha Tandon; Badria Munir; Muhammad Alvi; Amelia Adcock; Shitiz Sriwastava
Journal:  J Med Virol       Date:  2021-08-05       Impact factor: 20.693

9.  Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment.

Authors:  Na Li; Lingfeng Zhao; Xianquan Zhan
Journal:  J Cell Physiol       Date:  2020-09-22       Impact factor: 6.513

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.